Bookmark and Share
L 744832 (CID 6918276) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(17)
 
 
Unspecified(123)
 
 
Top Targets:
7tm 4(31)
 
 
 
p450(8)
 
 
 
Tryp SPc(2)
 
 
7tm 2(2)
 
 
prostaglandin..(2)
 
 
BioAssay Types:
Confirmatory(116)
 
 
 
Literature(8)
 
 
 
BioActivity Types:
IC50(119)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 140    Data Row: 140   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID104242266]
IC50 0.027Inhibition of FTase [AID587820, Type: Literature]
View
2
[SID104242266]
IC50 0.028DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) [AID625254, Type: confirmatory]D(3) dopamine receptor [gi:1169206]
View
3
[SID104242266]
IC50 0.122DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) [AID625149, Type: confirmatory]Melanocortin receptor 5 [gi:729996]
View
4
[SID104242266]
IC50 0.157DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) [AID625253, Type: confirmatory]D(2) dopamine receptor [gi:118206]
View
5
[SID104242266]
IC50 0.432DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) [AID625201, Type: confirmatory]Alpha-2A adrenergic receptor [gi:1351829]
View
6
[SID104242266]
IC50 0.54DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) [AID625225, Type: confirmatory]
View
7
[SID104242266]
IC50 0.7DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625249, Type: confirmatory]Cytochrome P450 2D6 [gi:84028191]
View
8
[SID104242266]
IC50 0.813DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625185, Type: confirmatory]Tyrosine-protein kinase Fyn [gi:125370]
View
9
[SID104242266]
IC50 1.609DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) [AID625227, Type: confirmatory]Substance-K receptor [gi:229462950]
View
10
[SID104242266]
IC50 3DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) [AID625251, Type: confirmatory]Cytochrome P450 3A4 [gi:116241312]
View
11
[SID104242266]
IC50 3.136DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) [AID625203, Type: confirmatory]Alpha-2C adrenergic receptor [gi:20141211]
View
12
[SID104242266]
IC50 3.216DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) [AID625184, Type: confirmatory]Epidermal growth factor receptor [gi:2811086]
View
13
[SID104242266]
IC50 3.395DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) [AID625147, Type: confirmatory]Melanocortin receptor 3 [gi:395398606]
View
14
[SID104242266]
IC50 3.568DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) [AID625215, Type: confirmatory]
View
15
[SID104242266]
IC50 3.568DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625152, Type: confirmatory]Muscarinic acetylcholine receptor M2 [gi:113122]
View
16
[SID104242266]
IC50 4.501DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) [AID625216, Type: confirmatory]
View
17
[SID104242266]
Induction of disorganization of tubulin in human PC3 cells assessed as microtubule bundles at 75 uM after 24 hrs by immunofluorescence microscopy [AID587825, Type: Literature]
View
18
[SID104242266]
IC50 75Anticancer activity against hormone-resistant human PC3 cells assessed as cell proliferation after 72 hrs by MTT assay [AID587817, Type: Literature]
View
19
[SID104242266]
IC50 78Anticancer activity against hormone-resistant human DU145 cells assessed as cell proliferation after 72 hrs by MTT assay [AID587816, Type: Literature]
View
20
[SID104242266]
Anticancer activity against human DU145 cells xenografted mouse assessed as suppression of tumor at 30 mg/kg [AID587821, Type: Literature]
View